Joon Bang

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Cell Proliferation

Cross Sectional

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Gaël Dos Santos, Raghavendra Devadiga, Chun Soo Kim, Joon Bang
An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older. Drug safety 47 (4) (2024)
Gaël Dos Santos, Raghavendra Devadiga, Chun Soo Kim, Joon Bang
An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older. Drug safety 47 (4) (2024)
Gaël Dos Santos, Raghavendra Devadiga, Chun Soo Kim, Joon Bang
An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older. Drug safety 47 (4) (2024)
Gaël Dos Santos, Raghavendra Devadiga, Chun Soo Kim, Joon Bang
An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older. Drug safety (2024)
Gaël Dos Santos, Raghavendra Devadiga, Chun Soo Kim, Joon Bang
An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older. Drug safety 47 (4) (2024)